What we do when we suppress fever

Current Infectious Disease Reports

Volumn 7, Issue 1, 2005, Pages 1-4

  Mackowiak, Philip A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; INDOMETACIN; INTERFERON; INTERFERON ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLANT EXTRACT; PYROGEN; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIA; ANTIPYRETIC ACTIVITY; ARTICLE; BACTEREMIA; BARK; CARDIOVASCULAR DISEASE; CHICKENPOX; CHINESE MEDICINE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; FEVER; GENETIC POLYMORPHISM; GRAM NEGATIVE BACTERIUM; HERBAL MEDICINE; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; HYPERTHERMIA; HYPOTENSION; HYPOTHERMIA; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INDUCED HYPOTHERMIA; INFECTION RESISTANCE; INFLUENZA; LETHALITY; LUNG VOLUME; MEAN ARTERIAL PRESSURE; MENTAL DISEASE; MORTALITY; MYRTLE; NONHUMAN; OXYGEN CONSUMPTION; PAIN; PATHOGENESIS; PATIENT CARE; PERITONITIS; PHYLOGENY; PHYSICAL TOLERANCE; PLANT LEAF; PREVALENCE; PROGNOSIS; PROTEIN SECRETION; RECURRENCE RISK; RESPIRATORY QUOTIENT; RESPIRATORY TRACT DISEASE; REYE SYNDROME; RHEUMATIC DISEASE; RHINOVIRUS; RISK BENEFIT ANALYSIS; SEIZURE; SEPSIS; SEPTIC SHOCK; SHIVERING; SHORT COURSE THERAPY; SIDE EFFECT; SURVIVAL; SYMPATHETIC TONE; THERMAL INJURY; VASCULAR RESISTANCE; WILLOW;

EID: 13544265647     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0016-y     Document Type: Article

References (47)

1. Oldach DW, Richard R, Borza EN, Benitez RM: A mysterious death. N Engl J Med 1998, 338:1764-1769.
2. O'Donnell J, Axelrod P, Fisher C, Lorber B: Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit. Clin Infect Dis 1997, 24:1208-1213.
3. Jack DB: One hundred years of aspirin. Lancet 1997, 350:437-439.
4. Mann J: Murder Magic, and Medicine. Oxford: Oxford University Press; 1992.
5. Vane JR, Flower RJ, Botting RM: History of aspirin and its mechanisms of action. Stroke 1990, 21(Suppl 4 ):IV12-IV23.
6. Kluger MJ, Kozak W, Conn CA, et al.: The adaptive value of fever. In Fever: Basic Mechanisms and Management, edn 2. Edited by Mackowiak PA. Philadelphia: Lippincott-Raven; 1997:255-266.
7. Mackowiak PA: Fever: blessing or curse? A unifying hypothesis. Ann Intern Med 1994, 120:1037-1040.
8. Mackowiak PA: Temperature regulation and the pathogenesis of fever. In Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GL, Douglas RG, Bennett JE. Philadelphia: Churchill Livingstone; 2000:604-622.
9. Kluger MJ, Ringler DH, Anver MR: Fever and survival. Science 1975, 188:166-168.
10. Bernheim HA, Klugher MJ: Fever: effect of drug-induced antipyresis on survival. Science 1976, 193:237-239.
11. Covert JR, Reynolds WW: Survival value of fever in fish. Nature 1977, 267:43-45.
12. Greisman SE: Cardiovascular alterations during fever. In Fever: Basic Mechanisms and Management. Edited by Mackowiak PA. New York: Raven Press; 1991:143-165.
13. Bryant RE, Hood AF, Hood CE, Koenig MG: Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971, 127:120-128.
14. Mackowiak PA, Browne RH, Southern PM Jr, Smith JW: Polymicrobial sepsis analysis of 184 cases using log linear models. Am J Med Sci 1980, 280:73-80.
15. Weinstein MR, Iannini PB, Staton CW, Eichoff TC: Spontaneous bacterial peritonitis, a review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978, 64:592-598.
16. Dorn TF, DeAngelis C, Baumgardner RA, et al.: Acetaminophen: more harm than good for chicken pox? J Pediatr 1989, 114:1045-1048.
17. Stanley ED, Jackson GG, Panusarn C, et al.: Increased viral shedding with aspirin treatment of rhinovirus infection. JAMA 1975, 231:1248-1251.
18. Graham MH, Burrell CJ, Douglas RM, et al.: Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990, 162:1277-1282.
19. Plaisance KI, Kudaravalli S, Wasserman SS, et al.: Effect of antipyretic therapy on duration of illness in experimental influenza A, Shigella sonnei and Rickettsia rickettsii infections. Pharmacotherapy 2000, 20:1417-1422.
20. Dinarello CA: Endogenous pyrogens. The role of cytokines in the pathogenesis of fever. In Fever: Basic Mechanisms and Management. Edited by Mackowiak PA. New York: Raven Press; 1991:23-47.
21. Bernheim HA, Bodel T, Askenase PW, Atkins E: Effects of fever on host defense mechanisms after injection of the lizard Dipsosaurus dorsalis. Br J Exp Pathol 1978, 59:76-84.
22. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991, 163:1177-1184.
23. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993, 119:771-778.
24. Mira JP, Cariou A, Grall F, et al.: Association of TNF 2, a TNF [alpha] promoter polymorphism, with septic shock susceptibility: a multicenter study. JAMA 1999, 282: 61-568.
25. Johnson J, Brigman KL, Jesmok G, Meyrick B: Morphologic changes in lungs of anesthetized sheep following intravenous infusion of recombinant tumor necrosis factor α. Am Rev Respir Dis 1991, 144:179-186.
26. Heinzel FP: The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 1990, 145:2920-2924.
27. Henricson BE, Neta R, Vogel SN: An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun 1991, 59:1188-1191.
28. Ohlsson K, Björk P, Bergenfeldt M, et al.: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348:550-552.
29. Opal SM, Cross AS, Sadoff JC, et al.: Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 1991, 88:885-890.
30. Overbeek BP, Veringa EM: Role of antibodies and antibiotics in aerobic gram-negative septicemia: possible synergism between antimicrobial treatment and immunotherapy. Rev Infect Dis 1991, 13:751-760.
31. Alexander HR, Sheppard BC, Jensen JC, et al.: Treatment with recombinant tumor necrosis factor-alpha protects rats against lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 1991, 88:34-39.
32. Fisher CJ Jr, Agosti JM, Opal SM, et al.: Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
33. Mackowiak PA, Boulant JA: Fever's glass ceiling. Clin Infect Dis 1996, 22:525-536.
34. Hirtz DG: Generalized tonic clonic and febrile seizures. Pediatr Clin North Am 1989, 36:365-382.
35. Berg AT: Febrile seizures and epilepsy: the contributions of epidemiology. Paediatr Perinat Epidemiol 1992, 6: 45-152.
36. Lessell S, Torres JM, Kurland LT: Seizure disorders in a Guamanian village. Arch Neurol 1962, 7:37-44.
37. Aicardi J: Febrile convulsions. In Epilepsy in Children, edn 2. Edited by Aicardi J. New York: Raven Press; 1994:253-275.
38. Lennox-Buchthal MA: Febrile Convulsions: A Reappraisal. Amsterdam: Elsevier; 1973.
39. Rosman NP: Febrile convulsions. In Fever: Basic Mechanisms and Management, edn 2. Edited by Mackowiak PA. Philadelphia: Lippincott-Raven; 1997:267-277.
40. Styrt B, Sugarman B: Antipyresis and fever. Arch Intern Med 1990, 150:1589-1597.
41. Horwath SM, Spurr GB, Hutt BK, Hamilton LH: Metabolic cost of shivering. J Appl Physiol 1956, 8:595-602.
42. Mackowiak PA, Plaisance KI: The benefits and risks of antipyretic therapy. Ann N Y Acad Sci 1998, 856:214-223.
43. Beisel WR, Morgan BB Jr, Bartelloni PJ, et al.: Symptomatic therapy in viral illness. A controlled study of effects on work performance. JAMA 1974, 228:581-584.
44. Plaisance KI, Mackowiak PA: Antipyretic therapy. Physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med 2000, 160:949-956.
45. Manthores CA, Hall JB, Olson D, et al.: Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med 1995, 151:10-14.
46. Raizner AE, Chahine RA, Ishimori T, et al.: Provocation of coronary artery spasm by the cold pressor test. Hemodynamic, arteriographic and quantitative arteriographic observations. Circulation 1980, 62:925-932.
47. Friedman PL, Brown EJ Jr, Gunther S, et al.: Coronary vasoconstrictor effect of indomethacin in patients with coronary artery disease. N Engl J Med 1981, 305:1171-1175.